Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Summary: Even with amazing new drugs, lung cancer with an EGFR mutation usually starts growing again at some point. When this happens, doctors face very tough choices about what treatment to use next. A new training program called "Show Me the Data" helps doctors figure out the best next steps. Experts debate real patient cases and look at new treatments, like special targeted antibodies, to find the safest and most effective options.

For more details, see rssapp-patientcareonline-com at gotoper.com/courses/show-me-the-data-post-tki-sequencing-in-egfr-mutated-nsclcoptimizing-current-strategies-and-preparing-for-new-treatment-modalities-2mm3?utm_source=patientcareonline&utm_medium=homePage&utm_campaign=cmeDeck (opens in new tab)